SCHEMBL22798301

SCHEMBL22798301

CC(=O)Nc1cc(C(=O)NCCNc2ncc(C(F)(F)F)cc2Cl)cc(C)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.59
ALDH1A1 P00352 6/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
POLB P06746 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
HTT P42858 3/20 0.47
MAPT P10636 2/20 0.47
HSP90AA1 P07900 2/20 0.47
XBP1 P17861 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 2/20 0.44
JAK2 O60674 1/20 0.44
PKM P14618 1/20 0.44
MC4R P32245 1/20 0.44
CCR6 P51684 1/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30449765 1.00 SCN9A (0.59) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL30449788 0.94 SCN9A (0.58) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL20595230 0.94 SCN9A (0.58) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL22798257 0.91 SCN9A (0.58) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL22798323 0.90 SCN9A (0.74) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL22798234 0.89 SCN9A (0.56) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL30449998 0.86 SCN9A (0.59) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL22798414 0.86 SCN9A (0.59) SCN9AALDH1A1KMT2AMEN1POLB
SCHEMBL22798309 0.84 SCN9A (0.59) SCN9AALDH1A1KMT2AMEN1MAPT
SCHEMBL22798304 0.84 SCN9A (0.82) SCN9AALDH1A1KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885ALDH1A1 2581/4885KMT2A 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.